{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke","description":" The VESALIUS\u2011CV trial demonstrated that adding the PCSK9 inhibitor evolocumab to optimized lipid\u2011lowering therapy significantly reduced the risk of first major cardiovascular events by 25% in high\u2011risk adults without prior heart attack or stroke and cut the risk of first heart attack by 36%. These results confirm that intensive LDL\u2011C lowering with evolocumab provides meaningful primary\u2011prevention benefits in patients with atherosclerosis or diabetes, achieving substantial event reduction over more than four years of follow\u2011up.  In this interview, Nanette Kass Wenger MD, MACC and Erin A. Bohula, MD, FACC discuss the VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke.  ","author_name":"ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research","author_url":"http:\/\/accelaccorg.libsyn.com\/website","html":"